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Medical treatment of adenoid hypertrophy with mometasone furoate
monohydrate nasal spray
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ﺔﺻﻼﺧﻟا:
ﻟاﺔﯾﻔﻠﺧ : ددﺣﺗﯾ مﺧﺿﺗ جﻼﻋو  ﺔﯾﻧادﻐﻟاءاوﮭﻟا ىرﺟﻣ دادﺳﻧا ﺔﺟردﻟ ﺎﻘﻓ رﺎﯾﺗﺧﺎﺑو فﻧﻷا ﻲﻓ رطﺎﺧﻣﻟا لﯾﻠﺣﺗو مﯾﯾﻘﺗ ﻲﻐﺑﻧﯾ ، ﻲﺣارﺟﻟا جﻼﻌﻟاو
 رﯾدﺧﺗﻟا تﺎﻔﻋﺎﺿﻣ ثﯾﺣ نﻣ ﻰﺿرﻣﻠﻟ ﺔﯾدرﻔﻟا ﻊﻓﺎﻧﻣﻟاوﺔﯾﺣارﺟﻟا ﺔﯾﻠﻣﻌﻟا.
 ،ﺔﻠﯾدﺑﻟا ﺔﯾﺟﻼﻌﻟا تارﺎﯾﺧﻟا نﻣ لﯾﻠﻗ ددﻋ كﺎﻧھ نأ نﻣ مﻏرﻟا ﻰﻠﻋدﯾورﯾﺗﺳﻠﻟ ﻲﻌﺿوﻣﻟا مادﺧﺗﺳﻻا رﺑﺗﻌﯾ رﯾﻏ ﺎﺟﮭﻧ  فﻧﻷا لﺧادﻲﺣارﺟ ﻲﻓ
و ، ةروطﺧ لﻗﻷا تﻻﺎﺣﻟاتدﻧﺗﺳا سﺎﺳﻷا اذھ ﻰﻠﻋﺔﺳاردﻟا هذھ.
 فدﮭﻟا  : تاردﯾھوﻧوﻣ تﯾوروﯾﻓ نوزﺎﺗﯾﻣوﻣﻟا جﻼﻋ مادﺧﺗﺳا رﯾﺛﺄﺗ مﯾﯾﻘﺗ )ﻷا ذاذرفﻧ ( مﺗﯾﺳ نﯾذﻟا ﻰﺿرﻣﻟا ددﻋ دﯾدﺣﺗو ﮫﯾﻧادﻐﻟا مﺧﺿﺗ ﻰﻠﻋ
ﻲﺣارﺟﻟا جﻼﻌﻟا نﻣ مھدﺎﻌﺑﺗﺳا
ﻟاﺔﯾﺟﮭﻧﻣ: نﻣ ةرﺗﻔﻠﻟ فﺟﻧﻟا ﺔظﻓﺎﺣﻣ ﻲﻓ ﺔﯾﺑطﻟا ردﺻﻟا ﺔﻧﯾدﻣ ﻲﻓ ﺔﺳاردﻟا هذھ تﯾرﺟأ31 رﺑﻣﺳﯾد2012 ﺔﯾﺎﻐﻟو31 رﺑﻣﺳﯾد2013.
 ﺎﯾﺋاوﺷﻋ ﻰﺿرﻣﻟا مﯾﺳﻘﺗ مﺗﻰﻟإ نﯾﺗﻋوﻣﺟﻣ . ﻰﻟوﻷا ﺔﻋوﻣﺟﻣﻟا نوزﺎﺗﯾﻣوﻣﻟا رﺎﻘﻌﺑ تﺟﻟوﻋﻓﯾوروﯾ تاردﯾھوﻧوﻣ ت )ذاذر قﯾرط نﻋفﻧﻷا (
ﺎھرادﻘﻣ ﺔﯾﺋاود ﺔﻋرﺟﺑو100 مارﻏورﻛﯾﻣ /موﯾ، )50لﻛﻟ مارﻏورﻛﯾﻣﻲﻓ ﺔﺣﺗﻓ فﻧﻷا (و ةدﻣﻟ12ﺎﻋوﺑﺳأ . ﺎھءﺎطﻋإ مﺗﻓ ﺔﯾﻧﺎﺛﻟا ﺔﻋوﻣﺟﻣﻟا ﺎﻣإ
 تارطﻗ ﮫﯾﺣﻠﻣ )دﯾاروﻠﻛ موﯾدوﺻ ( قﯾرط  نﻋ فﻧﻷاﻔﻟا سﻔﻧﻟ و ﺎﺿﯾأﺔﯾﻧﻣزﻟا ةرﺗ .ﻟ ﻰﺿرﻣﻟا ﻊﯾﻣﺟ ءﺎﻋدﺗﺳا مﺗﻠ لﻛ ﺔﻌﺑﺎﺗﻣ4ﻊﯾﺑﺎﺳأ.
 ﺞﺋﺎﺗﻧﻟا :دﻌﺑ12ﺎﻋوﺑﺳأجﻼﻌﻟا نﻣ ، زﯾﻣﻣ نﺳﺣﺗ دوﺟو ظﺣوﻟ ﻲﻓتﻘﻠﺗ ﻲﺗﻟا ﺔﻋوﻣﺟﻣﻟا جﻼﻌﻟاﺑﻟﺎدﯾورﯾﺗﺳ تﻘﻠﺗ ﻲﺗﻟا ﺔﻋوﻣﺟﻣﻟا ﻊﻣ ﺔﻧرﺎﻘﻣﻟﺎﺑ
جﻼﻌﻟا ﺔﯾﺣﻠﻣﻟا تارطﻘﻟﺎﺑﻷا دادﺳﻧا ثﯾﺣ نﻣمﻔﻟا قﯾرط نﻋ سﻔﻧﺗﻟاو فﻧ ، ضﻔﺧﻧا ثﯾﺣ طﺳوﺗﻣﺗ ﻲﺗﻟا ﺔﻋوﻣﺟﻣﻟا ضارﻋأ عوﻣﺟﻣ تﻘﻠ جﻼﻌﻟا
 دﯾورﯾﺗﺳﻟﺎﺑنﻣ12.82 ﻰﻟإ4.75ﻲﻓ لﺻﺎﺣﻟا رﯾﻐﺗﻟا نﺎﻛ ﺎﻣﻧﯾﺑ طﺳوﺗﻣضارﻋأ عوﻣﺟﻣ نﻣ  ﺎﻔﯾﻔط ىرﺧﻷا ﺔﻋوﻣﺟﻣﻟا12.53 ﻰﻟإ12.18.
جﺎﺗﻧﺗﺳﻻا :رﯾﺛﺄﺗ صﺣﻓ مﺗﯾ ،ﺔﺳاردﻟا هذھ ﻲﻓ نوزﺎﺗﯾﻣوﻣﻟاﻓﯾروو تاردﯾھوﻧوﻣ تﯾ)ذراذفﻧﻷا( مﺧﺿﺗ ﻰﻠﻋﻟاﺔﯾﻧادﻐ رﻓوﺗ ﺔﻘﯾرطﻟا هذھو ﺎﺟﻼﻋ
ﻲﺣارﺟﻟا جﻼﻌﻠﻟ ﻻﺎﻌﻓ ﻼﯾدﺑدﻧﻋ نﻣ نوﻧﺎﻌﯾ نﯾذﻟا لﺎﻔطﻷاﺔﯾﻧادﻐﻟا مﺧﺿﺗ نﻣ ﺞﺗﺎﻧﻟا مﻔﻟا قﯾرط نﻋ سﻔﻧﺗﻟاو فﻧﻷا دادﺳﻧا ضارﻋأ ، وﻊﻣقﯾﺑطﺗ
ﺔﺳاردﻟا هذھ،77.2 ﻰﺿرﻣﻟا نﻣ ٪دﺎﻌﺑﺗﺳا مﺗ مھنﻣﻲﺣارﺟﻟا جﻼﻌﻟا.
تﺎﯾﺻوﺗﻟا:ﻣ دﯾدﺣﺗ يرورﺿﻟا نﻣ فﻧﻷا دادﺳﻧا نﻣ نوﻧﺎﻌﯾ نﯾذﻟا لﺎﻔطﻸﻟ فﻧﻷا لﺧاد ﻲﻌﺿوﻣ جﻼﻌﻛ تادﯾورﯾﺗﺳﻟا مادﺧﺗﺳا نﻣ ةدﺎﻔﺗﺳﻻا ىد
 ﺔﯾﻧادﻐﻟا مﺧﺿﺗ نﻋ ﺞﺗﺎﻧﻟا
ثﺣﺑﻟا تادرﻔﻣ :ﺔﯾﻧادﻐﻟا ، نوزﺎﺗﯾﻣوﻣﻟاﻓﯾروو تاردﯾھوﻧوﻣ تﯾ)ذرذافﻧﻷا(
Abstract
Background: Treatment of adenoid hypertrophy is generally planned in accordance with the degree of airway
obstruction and related morbidity. If surgical treatment is indicated, the individual risk/ benefit analysis of
patients should be assessed in terms of anesthetic and postoperative complications.
Although there are few alternative treatment options, intranasal steroid applications may be considered as a
nonsurgical approach in less serious cases and have been presented in this study.
Objectives of the study: To assess  the effect of mometasone furoate monohydrate nasal spray on adenoid
hypertrophy and to determine how many patients will be  excluded from the  surgical treatment.
Patients and methods: A prospective, randomized, placebo controlled study was done in Al-Sader medical city
in Najaf from the period of 31 of Dec. 2012 to 31 of Dec. 2013. Patients indicated for surgery were randomly
divided into two groups. The study group was treated by mometasone furoate monohydrate nasal spray (NSS-
nasal steroid spray) of 100 micrograms/day (50 micrograms for each nostril) for 12 weeks. The control group
was treated by normal saline (NS) nasal drops in the same way. All the patients were followed-up every 4 weeks.
Results: At the end of 12 weeks, statistically significant improvement (p < 0.05) was observed in the NSS
treated group compared to the NS treated group in terms of nasal airway obstruction, mouth breathing, and night
cough. At the end of 12 weeks, the average total symptoms score of the NSS treated group dropped from 12.82
to 4.75 while the NS treated group’s score changed from 12.53 to 12.18. After 12 weeks of NSS treatment the
initial adenoid/choana (A/C) rate had dropped from 87.14 to 51.42%  and a total decrease of 35.72% was
observed. After 12 weeks of NS treatment the A/C rate dropped from 87.5 to 85% and a total decrease of 2.5%
was observed.
Conclusions: Treatment  with mometasone furoate monohydrate nasal spray provides an effective alternative to
surgical treatment in children with adenoid hypertrophy. With the protocol applied in this study 77.2% of the
patients were excluded from the surgery and removed from the surgical waiting list.
Recommendations: The reliability of nasal steroids for the pediatric population is widely recognized. Although
the mechanism itself has not yet been clearly and totally explained. We recommend that  it is important to
determine the role of intranasal corticosteroids in treating children with adenoid hypertrophy.
Keywords: adenoid hypertrophy, mometasone furoate monohydrate nasal spray
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INTRODUCTION
Adenoid is a lymphoid tissue located in the roof and posterior wall of the
nasopharynx. Adenoid hypertrophy is a common childhood disease. An enlarged
adenoid can occlude the choana, especially when sleeping in a supine position.
Symptoms due to airway obstruction like mouth breathing, hyponasal speech
and snoring in children are observed. [1] It may also cause otitis media with
effusion and accompanying conductive hearing loss and in the most serious
cases, obstructive sleeping apnea and accompanying growth retardation and cor-
pulmonale. [2],[3] Adenoid hypertrophy treatment for children is determined
according to the degree of airway obstruction and related morbidity. If surgical
treatment is indicated, the individual risk/ benefit analysis of patients should be
assessed in terms of anesthetic and postoperative complications. Although there
are few alternative treatment options, these may be considered as a nonsurgical
approach in less serious cases. [3] Accordingly, studies about intranasal steroid
applications under various protocols have been presented in the literature .
OBJECTIVES
To assess the effect of mometasone furoate monohydrate nasal spray on
adenoid hypertrophy and to determine how many patients will be  excluded from
the  surgical treatment.
PATIENTS AND METHODS
This is a prospective, randomized, placebo-controlled study of 65 patients with a
symptomatic and surgically indicated adenoid hypertrophy. The study had been
done in Al-Sader medical city in Najaf from the period of 31 of Dec. 2012 to 31
of Dec. 2013. Consent was obtained from the patients’ parents after they were
informed about the objectives of the study and the use of the drugs. Patients
needed to meet the following inclusion criteria in order to enter the study
(1)adenoid size occluding 75% of the nasopharynx, as determined with nasal
endoscopy;
(2) age between 5 to 15 years;
(3) symptoms consistent with adenoid hypertrophy lasting for at least 6 months;
(4) no previous adenoidectomy.
Patients with one or more of the following criteria were excluded from the study
(1)Children with concomitant tonsillar hypertrophy,
(2)Positive history of allergy or atopy,
(3)Upper respiratory infection within the past 2 weeks,
(4)Nasal anatomic anomalies (e.g., nasal septum deviation),
(5)Sinonasal diseases such as hypertrophy of inferior turbinate and/or nasal
polyposis,
(6)Craniofacial malformations including cleft lip/cleft palate,
(7)Genetic diseases (e.g., Down syndrome), neurologic disorders, cardiovascular
diseases, and immunodeficiency,
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(8)History of epistaxis or hypersensitivity to steroids,
At the beginning, clinical history was obtained from the parents with a
questionnaire and each child underwent physical evaluation and nasal
endoscopy. Patient history included age, gender, history and family history of
atopy or allergy, and use of drugs. Symptoms such as nasal obstruction, nasal
discharge, cough, snoring, and obstructive sleep apnea were also evaluated at the
first and at each subsequent visit, by using a clinical scoring system ranging
from 0 to 3 (0 = absent; 1 = occasional; 2 = frequent; 3 = daytime and nighttime
symptoms).[4] In this way, we gave each aforementioned symptom a score
related to severity. All scores were summed to obtain an overall symptom score
for each patient.
Nasal endoscopy was performed to estimate adenoid size and to identify other
sinonasal disorders. After local anesthesia administration and decongestion of
the nasal mucosa for 10 minutes with cotton pledgets soaked in xylocain,
endoscopic examination was conducted by using a rigid (2.7-mm diameter) or
flexible endoscope, according to the compliance of the child. Choanal openings
from top to bottom were graded (grade 1–4)[5] , and determined as:
1st grade: only top segment of the choana is obstructed (adenoid/choana
(A/C)rate is %25)
2nd grade: upper half of the choana is obstructed( A/C rate is %50)
3rd grade: Eustachian  tube opening is partially obstructed (A/C rate is %75)
4th grade: the choana is almost completely obstructed (A/C rate is 100%).
Patients indicated for surgery were then randomly divided into two groups. The
first group was treated by mometasone furoate monohydrate nasal spray (NSS-
nasal steroid spray) of 100 micrograms/day ( 50 micrograms for each nostril) for
12 weeks. The other group was treated by normal saline (NS) nasal drops . All
the patients were called for follow-up every 4 weeks.
SPSS 16.0 software was used for statistical analysis. When comparing the
groups, the independent sample t-test was applied. p values <0.05, were
accepted as statistically significant.
RESULTS
The demographic data for 65 patients is presented in Table (1),
Table (1) Age and gender distribution
Group No. of pt. Age (mean) Male Female
NSS 35 5-14 yr.(8.6) 13 22
NS 30 5-13 yr. (8.5) 17 13
Total 65 30 35
This table shows that among the total 65 patients, 30 patients were males and 35
were females. Also it shows that 35 patients were treated by the nasal steroid
spray(NSS). Their age ranging from 5 to 14 years with mean age equal to 8.6
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years. Among the 30 patients (control group) who were treated by the nasal
saline drops(NS), their age ranging from 5 to 13 years with mean age  equal to
8.5 years.
Table (2) Symptoms score distribution
Symptoms Average score before
treatment
Average score after treatment
(after 12 weeks)
NSS NS NSS NS
Nasal
discharge
2.74 2.8 0.85 2.53
Mouth
breathing
2.85 2.7 1 2.83
Snoring 2.83 2.83 0.8 2.83
Night cough 2 1.8 1.42 1.66
Sleep apnea 2.4 2.4 0.68 2.33
Total 12.82 12.53 4.75 12.18
P value 0.004 0.355
Table (2) shows that at the beginning of the treatment and at the end of the 12
weeks follow-up period, symptoms of nasal airway obstruction were  assessed.
By taking all the symptoms into consideration, the average total symptoms score
for each group was calculated and compared, (Fig. 1).
For both NSS and NS groups, the total symptoms scores were nearly similar
prior to the treatment. At the end of the 12 weeks, the average total symptoms
score of the NSS treated group dropped from 12.82 to 4.75 with a statistically
significant difference (t= 6.13 , p =0.004), while the NS treated group’s score
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Fig (1): Symptoms score distribution
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changed from 12.53 to 12.18 with a non significant difference (t= 1.04 ,  p =
0.355).
Figure (2) shows that the adenoid/choana (A/C) rate of the NSS treated group
after 12 weeks dropped from 87.14% to 51.42% and a total decrease of 35.72%
was observed. For the NS treated group the A/C rate after the 12 weeks dropped
from 87.5% to 85% and a total decrease of 2.5% was observed.
Table (3) Surgical need among the two groups
Group No. of pt. Not need surgery(%) Need surgery(%)
NSS 35 27(77.2) 8(22.8)
NS 30 0(0.0) 30(100)
Total 65 27 38
Table (3) shows that among the 35 patients who had NSS treatment, 27(77.2%)
patients  were not longer needing for surgery. Adenoidectomy was applied to 4
(11.4%) patients and the remaining 4 (11.4%) were informed of their ongoing
need for surgery but their parents refused the operation. Of the 30 patients who
were treated with normal saline, all of them (100%) underwent adenoidectomy.
DISCUSSION
Adenoid hypertrophy is probably the most frequent pathologic condition
occurring in the pediatric age group. It leads to different clinical manifestations
according to adenoid size. Bilateral nasal obstruction is a primary complaint that
can be associated with different sleep disorders, ranging from snoring to
OSAS[6]. In such a situation, patients typically complain of both nighttime and
daytime behavioral illnesses (i.e., intermittent sleep, sleepwalking, morning
headaches, difficulty concentrating, daytime sleepiness, enuresis, slow feeding,
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Fig (2): A/C rate before and after treatment
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and poor growth), which may lead to cardiorespiratory syndromes such as cor
pulmonale in extreme cases.[7] Rhinorrhea, mouth-breathing, hyponasal speech,
and cough can also be observed in patients with adenoid hypertrophy. At
present, adenoid hypertrophy is one of the most frequent indications for surgery
in childhood, and adenoidectomy commonly is considered definitive treatment
for nasopharyngeal obstruction.[8] Nevertheless, this surgical technique has been
the subject of some criticism. Paulussen et al[9] hypothesized that the removal of
adenoid lymphatic tissue could have a negative impact on the systemic
immunologic system. Moreover, immediate postoperative or late bleeding is
observed in 1% of children who undergo adenoidectomy. Furthermore, it is well
demonstrated that adenoids may recur after surgery in 10% to 20% of cases. [10]
In our study, the effect of mometasone furoate monohydrate nasal spray on
adenoid hypertrophy was assessed to determine how many patients will be
excluded from the  surgical treatment. At the end of 12 weeks treatment, a
statistically significant improvement in nasal airway obstruction symptoms was
observed in the nasal steroid spray( NSS) treated group compared to the normal
saline drops(NS) control group (p < 0.05). Patients’ average total symptoms
score dropped from 12.82to 4.75 in the NSS group and from 12.53 to 12.18 in
the control group. The average total symptom score of the NSS treated group
decreased by 63%. Regarding the adenoid size, after 12 weeks of treatment, the
decrease in the A/C rate was 35.72% in the NSS group and only 2.5% in the NS
group.
In 2005, Brouillette et al[11] tested the efficacy of another intranasal steroid
treatment for OSAS in a randomized, placebo-controlled clinical study by
studying the use of fluticasone propionate nasal spray versus placebo for 25
children affected by OSAS, as demonstrated with polysomnography. After
treatment, the mixed/obstructive apnea/ hypopnea index, frequency of
hemoglobin desaturation, and respiratory movement/arousals decreased more in
the fluticasone-treated group, compared with the placebo- treated group.
Moreover, improvements in symptom scores were observed for 69% of children
who received fluticasone.
In 2003, Criscuoli et al[12] by studying 53 children, they reported on the long-
term outcomes of treatment with aqueous nasal beclomethasone for patients with
adenotonsillar hypertrophy. Twenty four patients exhibited improvement after 2
weeks of steroid treatment, and an additional 24 weeks of therapy at a lower
steroid dose maintained clinical improvement  for 45.8% of those patients.
Recently, Cengel and Akyol[13] assessed the efficacy of Mometasone furoate
monohydrate in the treatment of  adenoid hypertrophy, in a prospective,
controlled, randomized, clinical trial. Of 122 patients enrolled, 67 received
intranasal Mometasone furoate monohydrate (100 mcg/day) therapy for 6
weeks, whereas 55 patients were assigned to the control group. After treatment,
a significant decrease of the adenoid mass was observed for 67.2% of the study
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group, whereas the clinical situation was unchanged in the control group. They
reported that the A/C rate decreased by 50%.
Ciprandi et al[4] showed significant decrease (p < 0.05) in average adenoid size
after 8 weeks of Flunisolide treatment compared to normal saline treatment.
Berlucchi et al[14] in a placebo-controlled study observed that the average
symptoms score dropped from 11 to 3 in the group treated by Mometasone
furoate spray and from 10 to 9 in the placebo treated control group. They also
observed a 20% decrease in average choanal obstruction in the Mometasone
group and 0.0% in the placebo group
Lepcha et al[15] reported, on the contrary to other studies, that although there was
a decrease in symptom scores after 12 weeks with Beclomethasone treatment , it
did not constitute a statistically significant difference comparing to placebo
control group’s scores .
Brouillette et al[11] also reported that reduction in adenotonsillar hypertrophy
caused by Fluticasone spray did not show statistically significant difference
compared to placebo.
Regarding the need for surgery after the nasal steroid treatment of the adenoid
hypertrophy, our study showed that among the 35 patients who had NSS
treatment, 27(77.2%) patients were not longer needing for surgery.
Adenoidectomy was applied to 4 (11.4%) patients and the remaining 4 (11.4%)
were informed of their ongoing need for surgery but their parents refused the
operation. Of the 30 patients who were treated with normal saline, all of them
(100%) underwent adenoidectomy.
Criscuoli et al[12] reported in their first long-term study that out of a total 24
patients who responded well to the initial treatment, 13 patients (54%) were still
in need of surgery. Berlucchi et al [14] informed that after Mometasone furoate
treatment only 2 of 39 patients who were indicated for adenoidectomy
underwent the surgery.
Corticosteroids are generally well tolerated in children. In our study, for each
nostril a maximum dose of 50 microgram/day, and for each patient total dose of
100 micrograms/day, was used for 12 weeks. We have not observed any side
effects in our patients.
CONCLUSION
This study provides an effective alternative to surgical treatment in children with
adenoid hypertrophy. With the protocol applied in this study 77.2 % of the
patients were no longer needing the surgery therefore they were removed from
the surgical waiting list. Intranasal corticosteroids are well tolerated by children;
however, the most appropriate drug, the most efficient dose and optimal
treatment duration continue to be investigated and determined by way of further
prospective and randomized studies.
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RECOMMENDATIONS
The reliability of nasal steroids for the pediatric population is widely recognized.
Although the mechanism itself has not yet been clearly and totally explained.
We recommend that it is important to determine the role of intranasal
corticosteroids in treating children with adenoid hypertrophy.
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